Holder Michael 4

What Happened
Michael Holder, a director of Cytek Biosciences, had 1,454 restricted stock units (RSUs) convert/settle into 1,454 shares on May 18, 2026 (transaction code M — exercise/conversion of a derivative). The filing shows 1,454 shares acquired (no acquisition price reported) and the identical 1,454 shares immediately reported as disposed at $0.00, so no cash proceeds are listed.

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 with the SEC.
• Reported amounts: 1,454 shares acquired (conversion of RSUs) and 1,454 shares disposed at $0.00.
• Price / value: Acquisition price not applicable; disposal price reported as $0.00 (no sale proceeds).
• Shares owned after transaction: Not specified in the provided filing information.
• Footnotes: F1 clarifies each RSU equals a contingent right to one share. F2 provides the multi-year vesting schedule (fractional vesting over 36 months with specified vesting dates).
• Filing timeliness: Form filed two days after the transaction date (May 20, 2026); the filing does not indicate a late-report flag in the provided data.
• Disposal note: The filing does not state the reason for the $0.00 disposals; filings commonly show similar disposals when shares are withheld or surrendered to cover taxes or related obligations, but that specific reason is not explicitly stated here.

Context
This was a derivative settlement (RSU conversion), not an open-market purchase or sale. Because the shares were reported acquired through conversion and immediately reported disposed at $0.00, this appears to be an administrative settlement rather than a market trade signaling a change in economic exposure. Retail investors often view purchases as stronger signals than administrative RSU settlements; treat this entry as a vesting/settlement disclosure rather than an indicator of directional insider buying or selling.